April 28, 2020 / 11:54 AM / a month ago

BRIEF-Ocular Therapeutix™ Announces Topline Results Of Phase 3 Clinical Trial Of Dextenza® For The Treatment Of Ocular Itching Associated With Allergic Conjunctivitis

April 28 (Reuters) - Ocular Therapeutix Inc:

* OCULAR THERAPEUTIX™ ANNOUNCES TOPLINE RESULTS OF PHASE 3 CLINICAL TRIAL OF DEXTENZA® FOR THE TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS

* OCULAR THERAPEUTIX INC - DATA FROM PHASE 3 CLINICAL TRIAL DEMONSTRATE STATISTICALLY SIGNIFICANT EFFECT ACHIEVED AT ALL PRE-SPECIFIED PRIMARY ENDPOINTS

* OCULAR THERAPEUTIX INC - INTENDS TO SUBMIT AN SNDA TO EXPAND DEXTENZA’S LABEL TO INCLUDE TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS IN 2020

* OCULAR THERAPEUTIX INC - IN PHASE 3 TRIAL, DEXTENZA MET ALL PRE-SPECIFIED PRIMARY ENDPOINTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below